| Lab Tests | CBC: 1-Sep-2024: RBC: 5.24*1012/L; HGB: 165 g/L; PLT: 291*109/L; WBC: 7.96*109/L; NEU: 55.4%; EOS: 1.4%; BAS: 1%; LYM: 33.1%; MON: 9.1%; ESR: 5 mm/hour. Biochemistry: 1-Sep-2024: Total protein: 69.7 g/L; Total bilirubin: 20 μmol/L; Direct bilirubin: 4.3 μmol/L; ALAT: 29.1 u/L; ASAT: 33.7 u/L; Creatinine: 120.3 μmol/L; Urea: 9 mmol/L; Glucose: 6.4 mmol/L; Total cholesterol: 6.4 mmol/L; HDL: 1.7 mmol/L; LDL: 1.15 mmol/L |
| Treatment of Concomitant Diseases | Medications: Ramipril 5 mg, per os, once a day, since Aug-2024 |
| Date of diagnosis | 2024/8/1 |
| Drinking History | Weekly drinker |
| MMSE | 11 |
| Race | Caucasian |
| Donor ID | 36363 |
| Height, cm | 184 |
| Treatment | Medications: Donepezil 10 mg, per os, once a day, since 1-Aug-2024 |
| Date of Draw | 2024/9/3 |
| Processing | Double spin |
| Weight, kg | 97 |
| Concomitant Diseases | Ischemic heart disease, Essential hypertension, Heart failure stage I, Cerebrovascular disease |
| Comments Data | Clinical symptoms: agnosia, aphasia, apraxia, impaired orientation in space and time, impaired fine motor skills, emotional lability, delirium, impaired intelligence; Date of CT: 2-Aug-2024; CT Conclusion: CT showed expressed atrophic process of the cerebral cortex. Cerebral microangiopathy Fazekas III. |
| Note | Visual Level of Hemolysis, 40-50 mg/dL. |
| Storage Condition | -70℃ |
| COVID-19 Vaccination | Vaccinated: Pfizer, 2 doses |
| HIV, HBV, HCV, RPR | Negative |
| Location Country | Ukraine |
| Smoking History | Current smoker (23 pack years, smoked for 23 years) |
| Cancer History and Relapses | |
